| Literature DB >> 29914956 |
Takashi Umeyama1, Yuta Hayashi2, Hisaki Shimosaka3, Tatsuya Inukai4, Satoshi Yamagoe4, Shogo Takatsuka4, Yasutaka Hoshino4, Minoru Nagi4, Shigeki Nakamura4, Katsuhiko Kamei5, Kenji Ogawa2, Yoshitsugu Miyazaki4.
Abstract
A pan-azole-resistant Aspergillus fumigatus strain with the cyp51A mutations Gly138Ser and Asn248Lys was isolated from a patient receiving long-term voriconazole treatment. PCR fragments containing cyp51A with the mutations were introduced along with the Cas9 protein and single guide RNA into the azole-resistant/susceptible strains. Recombinant strains showed increased susceptibility via the replacement of Ser138 by glycine. Genetic recombination, which has been hampered thus far in clinical isolates, can now be achieved using CRISPR/Cas9 genome editing.Entities:
Keywords: CRISPR; Cas9; Cyp51A; antifungal resistance; azole drugs; genome editing
Mesh:
Substances:
Year: 2018 PMID: 29914956 PMCID: PMC6125507 DOI: 10.1128/AAC.00894-18
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191